CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 168 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Bevacizumab 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01169558
NCT01169558Phase 3Completed
CompareCT.gov

First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum First BEAT (Bevacizumab Expanded Access Trial)- Brazilian Extension

Hoffmann-La Roche·interventional·Posted Jul 26, 2010·Updated Dec 8, 2016

In Brief

A Phase 3 clinical trial evaluating Bevacizumab and Fluoropyrimidine-based Chemotherapy for Colorectal Cancer. Completed, enrolled 168 participants across 28 sites.

Detailed Summary

This expanded access study will assess the safety and efficacy of intravenous bevacizumab (5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks) in combination with fluoropyrimidine-based chemotherapy as first line treatment in participants with metastatic cancer of the colon or rectum. The anticipated time on study treatment is 3-12 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesBrazil
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 26, 2010
Enrollment StartMay 1, 2006
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 15.9 years ago

Interventions

Bevacizumabdrug

5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.

Fluoropyrimidine-based Chemotherapydrug

Fluoropyrimidine-based chemotherapy administered according to standard of care.